Suppr超能文献

组织型纤溶酶原激活剂预防中心静脉通路装置感染:中心静脉通路导管血栓形成、感染及血栓预防的系统评价

Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis.

作者信息

Ragni M V, Journeycake J M, Brambilla D J

机构信息

Division Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213-4306, USA.

出版信息

Haemophilia. 2008 Jan;14(1):30-8. doi: 10.1111/j.1365-2516.2007.01599.x. Epub 2007 Nov 13.

Abstract

The recent unequivocal demonstration that prophylaxis, three to four weekly factor infusions, is effective in preventing joint disease in children with haemophilia, has provided impetus to initiate prophylaxis early in such children. Yet, nearly a quarter (22%) of the 83% who required central venous access devices for factor infusion developed central venous access catheter (CVAD)-related infection. This limitation of CVAD use prevents many families from initiating prophylaxis. The frequent occurrence of local thrombosis accompanying CVAD-related infection in surgical patients and autopsy cases, the thrombogenic plastic CVAD surfaces, and local clot formation at the insertion site, suggest the potential role of thrombolytic agents in preventing these infections. Yet, correlation between CVAD-related infection and local thrombosis in children with haemophilia are lacking, and thromboprophylaxis to prevent CVAD-related infection is controversial. Tissue plasminogen activator (t-PA), a recombinant serine protease glycoprotein that lyses plasmin-bound fibrin and is safe and effective in the treatment of occluded catheters, has not been evaluated in the prevention of these infections. We performed a literature review of CVAD-related infection, CVAD-related thrombosis, and thromboprophylaxis studies to evaluate the role of t-PA in the prevention of these infections in children with haemophilia. Metanalysis of published thromboprophylaxis trials demonstrate current prophylaxis regimens do not prevent CVAD infection, and further, that thrombosis and infection do not necessarily occur simultaneously. Pilot data demonstrate CVAD infection reduction in haemophilic children by monthly t-PA in 18 haemophilic children, suggesting the potential role of t-PA in CVAD infection prevention. Clinical trials to evaluate t-PA in CVAD infection prevention are justified.

摘要

最近明确证实,每三到四周进行一次因子输注的预防措施对预防血友病儿童的关节疾病有效,这推动了在此类儿童中尽早开始预防。然而,在83% 需要中心静脉通路装置进行因子输注的儿童中,近四分之一(22%)发生了中心静脉通路导管(CVAD)相关感染。CVAD使用的这一局限性使许多家庭无法开始预防。在外科手术患者和尸检病例中,CVAD相关感染常伴有局部血栓形成,CVAD的塑料表面具有血栓形成性,且在插入部位有局部血凝块形成,这表明溶栓剂在预防这些感染方面可能发挥作用。然而,血友病儿童中CVAD相关感染与局部血栓形成之间缺乏相关性,预防CVAD相关感染的血栓预防存在争议。组织纤溶酶原激活剂(t-PA)是一种重组丝氨酸蛋白酶糖蛋白,可溶解与纤溶酶结合的纤维蛋白,在治疗堵塞导管方面安全有效,但尚未在预防这些感染方面进行评估。我们对CVAD相关感染、CVAD相关血栓形成和血栓预防研究进行了文献综述,以评估t-PA在预防血友病儿童这些感染中的作用。对已发表的血栓预防试验的荟萃分析表明,目前的预防方案不能预防CVAD感染,而且血栓形成和感染不一定同时发生。初步数据表明,18名血友病儿童每月使用t-PA可降低CVAD感染率,这表明t-PA在预防CVAD感染方面可能发挥作用。开展评估t-PA预防CVAD感染的临床试验是合理的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验